BTB01303
Modify Date: 2024-09-16 06:53:39
BTB01303 structure
|
Common Name | BTB01303 | ||
|---|---|---|---|---|
| CAS Number | 652129-89-0 | Molecular Weight | 324.16 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C15H11Cl2NO3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BTB01303BTB01303 is a (glutamate release) inhibitor. Cancer cells release high levels of (glutamate), which disrupts normal bone turnover and may lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain[1]. |
| Name | BTB01303 |
|---|
| Description | BTB01303 is a (glutamate release) inhibitor. Cancer cells release high levels of (glutamate), which disrupts normal bone turnover and may lead to cancer-induced bone pain. BTB01303 has the potential to improve cancer-induced bone pain[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C15H11Cl2NO3 |
|---|---|
| Molecular Weight | 324.16 |
|
Name: Screen for inhibitors of RMI FANCM (MM2) intereaction
Source: 11908
Target: N/A
External Id: RMI-FANCM-MM2
|
|
Name: Inhibitors of CDC25B-CDK2/CyclinA interaction
Source: Center for Chemical Genomics, University of Michigan
External Id: MScreen:TargetID_600
|
Total 2, Current Page 1 of 1
1